Neurocrine Biosciences Inc (NBIX) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.

Total Assets Chart for Neurocrine Biosciences Inc

Neurocrine Biosciences Inc (NBIX) total assets for FY2025 were USD 4.6B, a 24.5% change from FY2024. Neurocrine Biosciences Inc's total assets grew from USD 78.0M in 1996 to USD 4.6B in 2025 (5837.8% over 29 years). Total assets compound annual growth rate: 5-year CAGR of 21.7%, 10-year CAGR of 25.6%, 20-year CAGR of 12.0%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$14.79B
Implied Share Price
$145.51
Enterprise Value
$14.42B
Revenue (TTM)
$3.37B
EBITDA
$913.30M
Profit Margin
20.91%
Trailing P/E
21.15
Forward P/E
14.12
Price/Book (MRQ)
3.90
Price/Sales (TTM)
4.38
EV/EBITDA
15.65
EV/Revenue
4.28
Dividend Yield
—
Book Value
$36.35
Free Cash Flow (FY2025)
$748.70M
Free Cash Flow Yield
5.06%

Snapshot as of 6th October 2026 — not point-in-time controlled, may lag the live market by a few days.